• S Todo, J J Fung, T E Starzl, A Tzakis, H Doyle, K Abu-Elmagd, A Jain, R Selby, O Bronsther, and W Marsh.
• Pittsburgh Transplant Institute, University of Pittsburgh Medical Center, Pennsylvania.
• Ann. Surg. 1994 Sep 1; 220 (3): 297-308; discussion 308-9.

ObjectiveThe efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined.Summary Background DataAfter 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejection with conventional immunosuppression, then as a primary drug.MethodsBetween August 1989 and December 1993, 1391 recipients (1188 adult and 203 pediatric) of primary liver allografts were treated with FK 506 from the outset. Results from these patients were analyzed and compared with those of 1212 historical control patients (971 adult and 241 pediatric) given cyclosporine-based immunosuppression.ResultsActuarial survival at 4 years was 86.2% with FK 506 versus 65.5% with cyclosporine in the pediatric patients (p < 0.0000) and 71.4% versus 65.5% in the adults (p < 0.0005). The need for retransplantation was reduced significantly for FK 506 patients. Four-year graft survival was 77.0% with FK 506 versus 48.4% with cyclosporine in the pediatric patients (p < 0.0000), and 61.9% with FK 506 versus 51.4% with cyclosporine in the adult recipients (p < 0.0000). Regression analysis revealed that reduction in mortality or graft loss from uncontrollable rejection, sepsis, technical failure, and recurrent original liver disease were responsible for the improved results with FK 506 therapy.ConclusionsFK 506 is a potent and superior immunosuppressive agent for orthotopic liver transplantation.

20 keywords...

hide…